MedTrace Logo

A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users

NCT00975481 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2013-04-02

Study results available
· View outcomes & findings →

Summary

Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).

Conditions

Interventions

DRUG

dimebon

Oral tablet; 20 mg dimebon, single dose

DRUG

dimebon

Oral tablet; 40 mg dimebon, single dose

DRUG

dimebon

Oral tablet; 60 mg dimebon, single dose

DRUG

placebo

Oral tablet or capsule; placebo, single dose

DRUG

alprazolam

Oral capsule; 1 mg alprazolam, single dose

DRUG

alprazolam

Oral capsule; 3 mg alprazolam, single dose

Sponsors & Collaborators

  • Medivation, Inc.

    collaborator INDUSTRY

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-02-28
Completion
2010-02-28

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00975481 on ClinicalTrials.gov